Real-World Clinical Outcomes In Patients Receiving Cyclin-Dependent Kinase 4/6 Inhibitors (Icdk 4/6) For Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (Hr+/Her2-) Metastatic Breast Cancer In Mexico.
JOURNAL OF CLINICAL ONCOLOGY(2020)
摘要
e13053Background: Breast cancer was the second most common malignant tumor diagnosed in 2018 worldwide, and the main cause of cancer death in women. In Mexico is the leading cause of cancer deaths,...
更多查看译文
关键词
Metastatic Breast Cancer,CDK4/6 Inhibitors,Breast Cancer
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要